首页> 外文期刊>Breast cancer research and treatment >Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases
【24h】

Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases

机译:临床淋巴结阳性乳腺癌患者新辅助化疗后残留腋窝病变的预后:孤立的肿瘤细胞和微转移瘤的预后优于巨转移瘤

获取原文
获取原文并翻译 | 示例

摘要

The aim of this study was to compare disease-free survival (DFS) and overall survival (OS) between clinically node-positive breast cancer patients, treated with neoadjuvant chemotherapy (NAC), with axillary pathologic complete response (ypN0), residual axillary isolated tumor cells or micrometastases (ypNitc/mi), and residual axillary macrometastases (ypN1-3).
机译:本研究的目的是比较接受新辅助化疗 (NAC) 治疗的临床淋巴结阳性乳腺癌患者的无病生存期 (DFS) 和总生存期 (OS),腋窝病理学完全缓解 (ypN0)、残余腋窝分离肿瘤细胞或微转移 (ypNitc/mi) 和残留腋窝巨转移 (ypN1-3)。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号